Neoadjuvant therapy is the preferred treatment mode for locally advanced operable esophageal cancer， and its clinical value has been established through evidence-based medical evidence. Accurately identifying patients who can benefit before or during treatment is of great significance for formulating the overall treatment strategy. Clinical indicators such as age， gender， pathological characteristics， nutritional status， and hematological/histological indicators have certain value in predicting the efficacy of neoadjuvant therapy for esophageal cancer. However， the predictive effect of a single indicator is limited. It is necessary to comprehensively use multiple indicators and combine advanced technologies and methods to provide accurate and practical tools for clinical efficacy prediction.